[Molecular pathology analysis of the KRAS mutation status in patients with metastasized colorectal carcinoma: an initial approach using predictive pathology].
作者信息
Tannapfel A
机构信息
Institut für Pathologie der Ruhr-Universität Bochum, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Bürkle-de-la-Camp-Platz 1, 44789, Bochum.
出版信息
Pathologe. 2008 Feb;29(1):93-6. doi: 10.1007/s00292-007-0966-y.
PMID:18210112
Abstract
摘要
相似文献
1
[Molecular pathology analysis of the KRAS mutation status in patients with metastasized colorectal carcinoma: an initial approach using predictive pathology].
Pathologe. 2008 Feb;29(1):93-6. doi: 10.1007/s00292-007-0966-y.
2
Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
J Clin Oncol. 2008 May 20;26(15):2600; author reply 2601-2. doi: 10.1200/JCO.2008.16.8195.
3
The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.
Arch Pathol Lab Med. 2009 Oct;133(10):1600-6. doi: 10.5858/133.10.1600.
4
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
J Clin Oncol. 2008 Jan 20;26(3):374-9. doi: 10.1200/JCO.2007.12.5906.
5
Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):525-9. doi: 10.1586/egh.10.62.
6
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
JAMA. 2010 Oct 27;304(16):1812-20. doi: 10.1001/jama.2010.1535.
7
KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
J Clin Oncol. 2008 May 1;26(13):2228-30; author reply 2230-1. doi: 10.1200/JCO.2007.15.9186.
8
FDA holds court on post hoc data linking KRAS status to drug response.
Nat Biotechnol. 2009 Feb;27(2):110-2. doi: 10.1038/nbt0209-110c.
9
Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
Eur J Cancer. 2010 Jul;46(10):1829-34. doi: 10.1016/j.ejca.2010.03.017. Epub 2010 Apr 24.
10
[Molecular pathologic KRAS mutation analysis. A prerequisite of effective antibody treatment for metastasized colorectal cancer].
Chirurg. 2008 Jun;79(6):576-9. doi: 10.1007/s00104-008-1514-x.
引用本文的文献
1
KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.
J Mol Diagn. 2010 Jan;12(1):35-42. doi: 10.2353/jmoldx.2010.090079. Epub 2009 Dec 10.
本文引用的文献
1
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
Ann Oncol. 2008 Mar;19(3):508-15. doi: 10.1093/annonc/mdm496. Epub 2007 Nov 12.
2
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
J Clin Oncol. 2007 May 1;25(13):1658-64. doi: 10.1200/JCO.2006.08.1620.
3
The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
Mol Cancer Res. 2007 Mar;5(3):203-20. doi: 10.1158/1541-7786.MCR-06-0404.
Zotero 插件